An oncolytic virus is a genetically engineered or naturally occurring virus that can imitate in selected terms and kill cancer cells without harming the normal tissues. Oncolytic Virus therapy is a new therapeutic approach for treating cancer and shown promising results globally.
Download free sample: https://www.datamintelligence.com/download-sample/oncolytic-virus-therapy-market
The rising prevalence of cancer cases and increasing development of cancer-treating therapies such as an oncolytic virus is driving the market growth globally.
Technological developments such as natural killer cells and use of combination therapies are also driving the market growth. Further ongoing development of virus therapies globally, which are in the pipeline will further enhance the growth of oncolytic virus therapy market in the forecast period.
The immune reaction to the virus-based therapies by repeated administration of therapeutics for treating cancer is a critical restraint that hampering market growth.
The high cost of oncolytic virus therapy is further affecting market growth, especially in developing countries.
By Drug Class
By Therapy Type
HSV-based Oncolytic Viruses
Adenoviruses-based Oncolytic Viruses
Vaccinia Virus-based Oncolytic Viruses
Vesicular Stomatitis Virus-based Oncolytic Viruses
Newcastle Disease Virus-based Oncolytic Viruses
By Geography the market is segmented into North America, South America, Europe, Asia Pacific and rest of the World. North America is the leading market globally and is mainly due to increased cancer cases associated with hectic lifestyles. Well-developed healthcare infrastructure is further supported by the growth in the region.
Oncolytic Virus Therapy is highly concentrated among a few key players such as Amgen, Shanghai Sunway Biotech Co. Ltd, and RIGVIR. Companies in the industry operate on low-profit margins, which is likely to worsen further during the forecast period. Industry players are focusing on implementing inorganic growth strategies to expand their presence in the market.